NSE: RUBICON | BSE: 544578

Expensive Performer

Download real time

1171.10 165.50 (16.46%)

4.0M NSE+BSE Volume

High volume+gain today

NSE 01 Jun, 2026 3:58 PM (IST)

19,333.9

Market Cap

High in industry

Rapid Results

Q4FY26 & FY26 Result Announced for Rubicon Research Ltd. See details

Rubicon Research Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for RUBICON, BSE:544578 Rubicon Research Ltd.

Search Inside the pdf :

Rubicon Research Ltd.

15 Apr 2026

1171.10

16.46%

Arinna acquisition: Unlocking distribution moat and domestic growth engine

Buy: Rubicon Research Ltd.

Target

Motilal Oswal

Rubicon Research (Rubicon) aims to make inroads into the central nervous system (CNS) therapy in India’s branded market (DF) through Arinna Lifescience (Arinna).

Rubicon Research has gained 78.56% in the last 6 Months

Rubicon Research Ltd.

18 Nov 2025

1171.10

16.46%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research Ltd. is trading at high volume of 3.8M with price gain of 16.46.

Rubicon Research Ltd.

13 Nov 2025

1171.10

16.46%

Outperformance across metrics; stellar start to the post-IPO phase

Buy: Rubicon Research Ltd.

Target

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research has gained 141.46% in the last 1 Year

Rubicon Research Ltd.

13 Nov 2025

1171.10

16.46%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research has gained 78.56% in the last 6 Months

Rubicon Research Ltd.

13 Nov 2025

1171.10

16.46%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research Ltd. is trading above all available SMAs

Rubicon Research Ltd.

13 Nov 2025

1171.10

16.46%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Number of FII/FPI investors decreased from 65 to 56 in Mar 2026 qtr

Rubicon Research Ltd.

13 Nov 2025

1171.10

16.46%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research has gained 20.74% in the last 1 Month

Rubicon Research Ltd.

13 Nov 2025

1171.10

16.46%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research has gained 20.74% in the last 1 Month

Rubicon Research Ltd.

31 Oct 2025, 12:00AM

1171.10

16.46%

Gains in the gale

Buy: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research is a fast-growing research and development-driven pharmaceutical manufacturing company with a focus on regulated markets (particularly the US).

Rubicon Research Ltd. is trading above all available SMAs

Rubicon Research Ltd.

09 Oct 2025

1171.10

16.46%

RUBICON RESEARCH INDIA LIMITED

IPO Subscribe: Rubicon Research Ltd.

Hem Securities

Company is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States. Based on the peer set (of seven listed Indian companies assessed by F&S, and Company), company is the only Indian pharmaceutical player with a complete focus on regulated markets. Between Fiscals 2023 and 2025, company was...